Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 2:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Painful Diabetic Neuropathy Clear all
Terminated Not applicable Interventional Accepts healthy volunteers

MR(Magnetic Resonance) Imaging of Neurotransmitters in Chronic Pain

NCT01620775
View directory record Official record
Conditions
Chronic Low Back Pain, Diabetic Peripheral Neuropathy, Knee Osteoarthritis
Interventions
MRIs, Pain testing
Other
Lead sponsor
University of Michigan
Other
Eligibility
30 Years to 70 Years
Enrollment
87 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 3, 2018 · Synced Jun 10, 2026, 2:09 PM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability and Preliminary Efficacy of AZD5213 in Combination With Pregabalin in Subjects With PDN and Good Pain Reporting Ability

NCT01928381
View directory record Official record
Conditions
Diabetic Neuropathy, Painful; Diabetic Neuropathies
Interventions
AZD5213 + pregabalin, Placebo, pregabalin capsules
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
9
States / cities
Clearwater, Florida • Orlando, Florida • Newnan, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2016 · Synced Jun 10, 2026, 2:09 PM EDT
Not listed Phase 4 Interventional

Evaluation of the Impact of Training on Outcome Measures in Subjects With Painful Diabetic Neuropathy

NCT01770964
View directory record Official record
Conditions
Diabetes Mellitus, Painful Distal Symmetric Sensorimotor Polyneuropathy
Interventions
Pregabalin, placebo, Training Type A, Training Type B
Drug · Behavioral
Lead sponsor
Analgesic Solutions
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
6
States / cities
Brighton, Massachusetts • Watertown, Massachusetts • Johnson City, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2013 · Synced Jun 10, 2026, 2:09 PM EDT
Withdrawn Phase 2 Interventional

Efficacy and Safety of VM202 in Painful Diabetic Peripheral Neuropathy -The HOPES Trial

NCT04087941
View directory record Official record
Conditions
Painful Diabetic Neuropathy
Interventions
VM-202
Biological
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 27, 2025 · Synced Jun 10, 2026, 2:09 PM EDT
Completed Phase 2 Interventional Results available

A Safety Study of Clonidine Hydrochloride Topical Gel, 0.1% in the Treatment of Painful Diabetic Neuropathy

NCT02355158
View directory record Official record
Conditions
Painful Diabetic Neuropathy, Diabetes
Interventions
clonidine hydrochloride topical gel, 0.1%
Drug
Lead sponsor
BioDelivery Sciences International
Industry
Eligibility
18 Years to 85 Years
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
20
States / cities
Phoenix, Arizona • Santa Monica, California • Walnut Creek, California + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2017 · Synced Jun 10, 2026, 2:09 PM EDT
Completed Phase 4 Interventional

An Open Label, Dose Finding Trial of Viagra for the Treatment of Neuropathic Pain (in Diabetes Mellitus)

NCT00194909
View directory record Official record
Conditions
Diabetic Neuropathy
Interventions
sildenafil (Viagra)
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 24, 2008 · Synced Jun 10, 2026, 2:09 PM EDT
Completed Not applicable Interventional Results available

Dual Field PEMF Therapy in Lower Extremity Painful Diabetic Distal Symmetric Peripheral Neuropathy

NCT03455543
View directory record Official record
Conditions
Diabetic Neuropathy Peripheral
Interventions
Active Provant Therapy System, Inactive (sham) Provant Therapy System
Device
Lead sponsor
Regenesis Biomedical, Inc.
Industry
Eligibility
22 Years to 80 Years
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
18
States / cities
Mesa, Arizona • Northridge, California • Sacramento, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2020 · Synced Jun 10, 2026, 2:09 PM EDT
Completed Phase 2 Interventional

EPPIC-Net: Platform Protocol to Assess Treatments for Painful Diabetic Peripheral Neuropathy

NCT05476276
View directory record Official record
Conditions
Painful Diabetic Neuropathy
Interventions
ISA specific
Drug
Lead sponsor
James P. Rathmell, MD
Other
Eligibility
18 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
23
States / cities
San Diego, California • Clermont, Florida • Gainesville, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Jun 10, 2026, 2:09 PM EDT
Active, not recruiting Phase 3 Interventional

Evaluation of the Long-term Safety and Effectiveness of Suzetrigine (SUZ) in Participants With Painful Diabetic Peripheral Neuropathy (DPN)

NCT06696443
View directory record Official record
Conditions
Diabetic Peripheral Neuropathic Pain
Interventions
Suzetrigine
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 80 Years
Enrollment
455 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
65
States / cities
Anniston, Alabama • Daphne, Alabama • Scottsdale, Arizona + 60 more
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced Jun 10, 2026, 2:09 PM EDT
Terminated Phase 2 Interventional

A Study of Effectiveness and Safety of JNJ-42160443 in Patients With Diabetic Painful Neuropathy

NCT00993018
View directory record Official record
Conditions
Diabetic Neuropathy
Interventions
JNJ-42160443 (1 mg), JNJ-42160443 (3 mg), JNJ-42160443 (10 mg), Placebo
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 80 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
23
States / cities
Jonesboro, Arkansas • Fresno, California • La Jolla, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2016 · Synced Jun 10, 2026, 2:09 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Assessing Symptom and Mood Dynamics in Pain Using the Smartphone Application SOMA

NCT05754190
View directory record Official record
Conditions
Chronic Pain, Acute Pain, Post Operative Pain, Fibromyalgia, Primary, Fibromyalgia, Secondary, Fibromyalgia, Irritable Bowel Syndrome, Chronic Headache Disorder, Chronic Migraine, Chronic Pelvic Pain Syndrome, Temporomandibular Joint Disorders, Endometriosis-related Pain, Arthritis, Chronic Low-back Pain, Failed Back Surgery Syndrome, Post Herpetic Neuralgia, Neuropathic Pain, Painful Diabetic Neuropathy, Painful Bladder Syndrome, Trauma-related Wound, Trauma, Multiple, Chronic Pain Syndrome, Chronic Shoulder Pain
Interventions
SOMA pain manager smartphone application
Device
Lead sponsor
Brown University
Other
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced Jun 10, 2026, 2:09 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Efficacy and Safety of a Single Application of Capsaicin 8%Transdermal Delivery System Compared to Placebo in Reducing Pain Intensity in Subjects With Painful Diabetic Peripheral Neuropathy (PDPN)

NCT01533428
View directory record Official record
Conditions
Diabetic Peripheral Neuropathy, Pain
Interventions
Capsaicin 8%, Placebo
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
369 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
29
States / cities
Anniston, Alabama • Fresno, California • Long Beach, California + 24 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2015 · Synced Jun 10, 2026, 2:09 PM EDT
Recruiting Not applicable Interventional

The Treatment of Painful Diabetic Neuropathy With Diet

NCT07509671
View directory record Official record
Conditions
Painful Diabetic Neuropathy (PDN), Peripheral Neuropathy With Type 2 Diabetes, Vegan Diet
Interventions
Diet, Medical management
Other
Lead sponsor
AdventHealth
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Hendersonville, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Jun 10, 2026, 2:09 PM EDT
Completed Phase 4 Interventional

A Study of the Effectiveness And Safety Of Lidoderm® As Add-On Treatment in Patients With Postherpetic Neuralgia, Diabetic Neuropathy, or Low Back Pain

NCT00904020
View directory record Official record
Conditions
Postherpetic Neuralgia, Diabetic Neuropathy, Low Back Pain
Interventions
Lidoderm
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
11
States / cities
Birmingham, Alabama • Phoenix, Arizona • Plantation, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 1, 2024 · Synced Jun 10, 2026, 2:09 PM EDT
Completed Phase 3 Interventional

Evaluating the Safety and Tolerability of OraVescent Fentanyl for Opioid Tolerant Patients With Noncancer Related Breakthrough Pain

NCT00228605
View directory record Official record
Conditions
Low Back Pain, Migraine, Diabetic Neuropathies, Osteoarthritis
Interventions
OraVescent Fentanyl
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years to 80 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
38
States / cities
Calera, Alabama • Hoover, Alabama • Phoenix, Arizona + 29 more
Source: ClinicalTrials.gov public record
Updated May 8, 2014 · Synced Jun 10, 2026, 2:09 PM EDT
Active, not recruiting Phase 2 Interventional

Effects of LY3848575 Versus Placebo in Participants With Painful Distal Sensory Polyneuropathy

NCT06568042
View directory record Official record
Conditions
Neuropathic Pain, Distal Sensory Polyneuropathy
Interventions
LY3848575, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
558 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
24
States / cities
Chandler, Arizona • Phoenix, Arizona • Fresno, California + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Jun 10, 2026, 2:09 PM EDT
Completed Phase 3 Interventional

Trial to Assess the Efficacy and Safety of SPM 927 (200, 400, and 600mg/Day) in Subjects With Painful Distal Diabetic Neuropathy

NCT00135109
View directory record Official record
Conditions
Diabetic Neuropathies
Interventions
SPM 927
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
654 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
RTP, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 21, 2014 · Synced Jun 10, 2026, 2:09 PM EDT
Withdrawn Not applicable Interventional

Peripheral Nerve Responses to Focal Vibration and Implications in Pain and Mobility for Patients With Diabetic Peripheral Neuropathy

NCT05041816
View directory record Official record
Conditions
Diabetic Peripheral Neuropathy
Interventions
Focal vibration therapy
Device
Lead sponsor
University of Oklahoma
Other
Eligibility
45 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Mar 5, 2024 · Synced Jun 10, 2026, 2:09 PM EDT
Completed Phase 2 Interventional

A Study of LY3556050 in Adult Participants With Diabetic Peripheral Neuropathic Pain

NCT06074562
View directory record Official record
Conditions
Diabetic Peripheral Neuropathy
Interventions
LY3556050, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
405 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
34
States / cities
Chandler, Arizona • Scottsdale, Arizona • Tucson, Arizona + 30 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced Jun 10, 2026, 2:09 PM EDT
Active, not recruiting Phase 2 Interventional

A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy

NCT06797869
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Diabetic Peripheral Neuropathy
Interventions
CagriSema (Cagrilintide B and Semaglutide I), Placebo matched to CagriSema (Cagrilintide B and Semaglutide I)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
19
States / cities
La Mesa, California • San Diego, California • Miami, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2025 · Synced Jun 10, 2026, 2:09 PM EDT
Terminated Not applicable Interventional Results available

An Evaluation of the Effect of Low Level Laser Therapy on Diabetic Peripheral Neuropathy Pain

NCT04006392
View directory record Official record
Conditions
Diabetic Peripheral Neuropathy
Interventions
Erchonia FX-635, Placebo Laser
Device
Lead sponsor
Erchonia Corporation
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
4
States / cities
Mesa, Arizona • Costa Mesa, California • Hialeah, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2023 · Synced Jun 10, 2026, 2:09 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of NYX-2925 in Subjects With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy

NCT03219320
View directory record Official record
Conditions
Diabetic Peripheral Neuropathy
Interventions
NYX-2925, Placebo
Drug
Lead sponsor
Aptinyx
Industry
Eligibility
18 Years to 75 Years
Enrollment
301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
35
States / cities
Phoenix, Arizona • Anaheim, California • Fresno, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2020 · Synced Jun 10, 2026, 2:09 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study for the Treatment of Painful Diabetic Neuropathy

NCT01475786
View directory record Official record
Conditions
Painful Diabetic Neuropathies
Interventions
Low Dose: 16 mg Engensis (VM202), High Dose: 32 mg Engensis (VM202), Control- Placebo (normal saline)
Biological · Other
Lead sponsor
Helixmith Co., Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
13
States / cities
Walnut Creek, California • Orlando, Florida • Palm Beach Gardens, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2025 · Synced Jun 10, 2026, 2:09 PM EDT
Completed Phase 2 Interventional Results available

The Efficacy and Safety of Clonidine Hydrochloride Topical Gel, vs Clonidine Hydrochloride Gel Comparator to Treat Painful Diabetic Neuropathy

NCT02643251
View directory record Official record
Conditions
Painful Diabetic Neuropathy, Diabetic Neuropathy, Neuropathy
Interventions
Clonidine Hydrochloride Topical Gel, 0.1%, Clonidine Hydrochloride Gel Comparator
Drug
Lead sponsor
BioDelivery Sciences International
Industry
Eligibility
18 Years and older
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
25
States / cities
Glendale, Arizona • Phoenix, Arizona • Anaheim, California + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2017 · Synced Jun 10, 2026, 2:09 PM EDT